Bace1 Inhibitors For Alzheimer'S Disease is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
BACE1 (Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1), also known as beta-secretase, is a crucial enzyme in the production of amyloid-beta (Aβ) peptides that accumulate in the brains of Alzheimer's disease patients. BACE1 inhibitors represent one of the most intensively pursued therapeutic strategies for Alzheimer's disease prevention and treatment, targeting the upstream amyloid cascade.
BACE1 is an aspartyl protease that catalyzes the first and rate-limiting step in the amyloidogenic processing of amyloid precursor protein (APP). The enzymatic cleavage produces sAPPβ and C99, which is subsequently cleaved by gamma-secretase to release amyloid-beta peptides (Aβ40 and Aβ42).
APP → (BACE1) → sAPPβ + C99 → (γ-secretase) → Amyloid-beta peptides
The BACE1 reaction is the initial and rate-limiting step in amyloid-beta generation, making it an attractive therapeutic target for reducing amyloid-beta production.
Several BACE1 inhibitors have progressed to late-stage clinical trials but failed due to safety concerns or lack of efficacy:
| Drug | Company | Phase | Outcome |
|---|---|---|---|
| Verubecestat (MK-8931) | Merck | Phase III | Terminated due to cognitive decline |
| Lanabecestat (AZD3293) | AstraZeneca/Eli Lilly | Phase III | Terminated for lack of efficacy |
| Atabecestat (JNJ-54861911) | Janssen | Phase II/III | Terminated due to liver toxicity |
| Elenbecestat (E2609) | Eisai | Phase II | Terminated due to brain volume loss |
Some BACE1 inhibitors continue to be investigated:
The failure of BACE1 inhibitors in late-stage trials provided important lessons:
Rather than complete inhibition, partial modulation of BACE1 activity may provide benefits while reducing side effects:
Future approaches may combine BACE1 modulation with:
The study of Bace1 Inhibitors For Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Hampel, H., et al. (2021). Beta-secretase BACE1 in Alzheimer's disease: targeting a pivotal therapeutic node. Molecular Psychiatry, 26(8), 4084-4103.
[2] Egan, M. F., et al. (2018). Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease. New England Journal of Medicine, 378(18), 1691-1703.
[3] Henley, D. B., et al. (2019). Development of APH-1105 and BACE inhibitors: lessons learned. Journal of Prevention of Alzheimer's Disease, 6(3), 153-157.
[4] Ghosh, A. K., & Brindisi, M. (2020). Developing BACE1 inhibitors for Alzheimer's disease: an overview. Journal of Medicinal Chemistry, 63(13), 7208-7241.
[5] Takahashi, R. H., et al. (2020). BACE1 inhibition: too much or too little? Acta Neuropathologica Communications, 8(1), 1-15.
[6] Neumann, U., et al. (2018). The BACE inhibitor verubecestat (MK-8931) reduces CNS beta-amyloid in animal models and in people with Alzheimer's disease. Science Translational Medicine, 10(461), eaat8794.
[7] Das, B., & Yan, R. (2019). BACE1: functions and therapeutic potential for Alzheimer's disease. Cellular and Molecular Neurobiology, 39(2), 165-180.
[8] Blennow, K., et al. (2019). BACE1 in cerebrospinal fluid as a biomarker for Alzheimer's disease. Lancet Neurology, 18(9), 800-801.